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Abstract
Background: Fabry disease (FD) is caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA) resulting in
the accumulation of globotriaosylsphingosine (Gb3) in a variety of tissues. While GLA deficiency was always considered as
the fulcrum of the disease, recent attention shifted towards studying the mechanisms through which Gb3 accumulation in
vascular cells leads to endothelial dysfunction and eventually multiorgan failure. In addition to the well-described
macrovascular disease, FD is also characterized by abnormalities of microvascular function, which have been demonstrated
by measurements of myocardial blood flow and coronary flow reserve. To date, the relative importance of Gb3
accumulation versus GLA deficiency in causing endothelial dysfunction is not fully understood; furthermore, its differential
effects on cardiac micro- and macrovascular endothelial cells are not known.
Methods and Results: In order to assess the effects of Gb3 accumulation versus GLA deficiency, human macro- and
microvascular cardiac endothelial cells (ECs) were incubated with Gb3 or silenced by siRNA to GLA. Gb3 loading caused
deregulation of several key endothelial pathways such as eNOS, iNOS, COX-1 and COX-2, while GLA silencing showed no
effects. Cardiac microvascular ECs showed a greater susceptibility to Gb3 loading as compared to macrovascular ECs.
Conclusions: Deregulation of key endothelial pathways as observed in FD vasculopathy is likely caused by intracellular Gb3
accumulation rather than deficiency of GLA. Human microvascular ECs, as opposed to macrovascular ECs, seem to be
affected earlier and more severely by Gb3 accumulation and this notion may prove fundamental for future progresses in
early diagnosis and management of FD patients.
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Introduction
Fabry disease (FD) is an X-linked lysosomal storage disease
secondary to deficiency of the lysosomal enzyme alpha-
galactosidase A (GLA) where globotriaosylsphingosine (Gb3) –
the primary GLA substrate – accumulates in a variety of tissues
[1]. While GLA deficiency was always considered as the fulcrum
of the disease, in the last decade the main focus of attention
shifted towards studying the mechanisms through which Gb3
accumulation – the main offending metabolite – leads to
multiorgan failure as observed in FD. Premature multiorgan
damage occurs in patients with FD most frequently on the
grounds of endothelial dysfunction caused by accumulation of
Gb3 in vascular endothelial cells [2]. In addition to the well-
described macrovascular disease, FD is also characterized by
microvascular function abnormalities, which have been docu-
mented by measurements of myocardial blood flow and coronary
flow reserve [3,4]. Furthermore, a survey of female patients with
FD revealed that cardiac ischemia could be confirmed by
electrocardiographic changes and serological markers in the
absence of epicardial coronary artery stenosis, suggesting that
ischemia in these patients was of microvascular origin [5]. While
a mouse model of GLA deficiency has facilitated the study of
glycosphingolipid metabolism abnormalities on macrovascular
end points [6] the mechanisms by which GLA deficiency causes
microvascular dysfunction remain to be defined.
Hence, this study focuses on analyzing the regulation of key
mediators of endothelial function following Gb3 loading or GLA
silencing. Additionally, to elucidate differences between macro-
and microvascular endothelium, human macro- and microvas-
cular cardiac endothelial cells were used in parallel.
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Materials and Methods
Cells
Human cardiac microvascular endothelial cells (HMiVECs) and
macrovascular endothelial cells (HMaVECs) (Clonetics, Allschwil,
Switzerland) were cultured in EGM-2 medium containing 2% or
10% FBS, respectively, and the supplements given by the
manufacturer. Cells were grown to confluence in 3 cm dishes
and rendered quiescent for 48 hours before stimulation with 5 ng/
mL TNF-a. Cells were pretreated with Gb3 (1024 M) for
48 hours. Cytotoxicity was assessed with a colorimetric assay to
detect lactate dehydrogenase release (Roche, Basel, Switzerland).
Gb3-preparation and loading
An aliquot of Gb3 (Matreya, Pleasant Gap, PA) dissolved in
chloroform and methanol was air-dried and resuspended in
DMSO. The resulting compound was then heated at 90uC for
10 min with occasional vortexing. Finally, an appropriate amount
of fatty acid-free bovine serum albumin (BSA, Sigma), dissolved in
phosphate buffered saline (PBS) was added to achieve a 1:1 molar
ratio of Gb3/albumin complex. The complex was then sonicated
for 5 minutes in a water bath sonicator (Transsonic 460, Elma).
Finally, the complex was diluted into EGM medium (Lonza),
containing 0.5% FCS. Cultures of endothelial cells were incubated
with the medium containing Gb3/albumin complex for 48 hrs.
Western blot
Protein expression was determined by Western blot analysis as
described previously [7,8]. Antibodies against human ICAM-1
(Invitrogen, Carlsbad, CA, USA) and VCAM-1 (R&D Minneap-
olis, MN, USA) were used at 1:1000 and 1:2000 dilutions,
respectively. Antibodies against total eNOS, phosphorylated
eNOS, and iNOS (all from Cayman Chemicals, Ann Arbor, MI,
USA) were used at 1:5000, 1:2000, and 1:2000 dilutions,
respectively. Antibodies against COX-1 and COX-2 (all from
Cayman Chemicals, Ann Arbor, MI, USA) were used at 1:2000,
and 1:1000 dilutions, respectively. Rabbit anti-alpha-galactosidase
A polyclonal antibody (Lab Force, Switzerland) was used at 1:5000
dilution. All blots were normalized to Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Chemicon, Temecula, CA, 1:20000
dilution).
GLA gene silencing through siRNA transfection
Four siRNA sequences specific for human GLA were applied for
knocking down GLA expression using the HiPerFect siRNA
Transfection System (Qiagen). These siRNA sequences were
purchased from Microsynth and were as follows (siRNA 1, 59-
UAAAACCUGCGCAGGCUUCUUTT-39; siRNA 2, 59-AUCC-
GACAGUACUGCAAUCUUTT-39; siRNA 3, 59-UUGCCAU-
CAA-UCAGGACCCUUTT-39; siRNA 4, 59-GUGUGGGAAC-
GACCUCUCUUUTT-39). Briefly, cells were transfected with a
45 nM siRNA
HiPerFect transfection solution and incubated with transfection
serum-free medium for the following 4 hrs at 37uC. Subsequently,
cells were cultured in the serum-containing growth medium for
48 hrs at 37uC.
Gb3 ELISA
A 96 well plate was coated with BGR23 IgG2b antibody
(Seikagaku, Japan, 1:500 dilution) for 8 h. Then 5% milk buffer
was added for 1 h. This was followed by addition of endothelial
cell lysate and incubation with mouse IgM DMAB-1 antibody
(kindly provided by J.E. Mansson, Sweden) at 1:100 dilution for
8 h. Subsequently, wells were washed three times with 1% PBS
Tween and then a secondary IgM antibody conjugated to
horseradish peroxidase was added. Wells were then washed three
times and incubated with substrate solution. Finally, colorimetric
readout was measured at 450 nm by spectrophotometry. A
standard curve with Gb3 was performed to assure that
measurements were taken in the linear range of detection.
Statistics
Data were analyzed using the Mann–Whitney U-test to
compare group means. Results are expressed as mean6standard
error of mean (SEM). A P-value,0.05 was considered to represent
a significant difference.
Results
Gb3 loading and GLA gene silencing
Incubation of HMaVECs or HMiVECs with Gb3 increased
intracellular concentration of Gb3, as measured by ELISA 2-fold
(n = 4, p = 0.03 and p= 0.04, respectively, versus untreated
control, Figure 1A). To control for potential toxic effects,
HMaVECs and HMiVECs were treated with 1024 M Gb3 for
48 hrs. Morphological examination under a light microscope did
not reveal any morphological changes (n = 4; shown in data
supplement Figure S1).
To downregulate GLA expression in HMaVECs and HMi-
VECs, siRNA was used. Four different siRNA oligonucleotide
sequences on the basis of the human GLA mRNA were designed
and applied. A maximal GLA protein silencing of 70% was
observed under these conditions (Figure 1B) 48 hrs after
transfection in the absence of any toxic effect as measured by
LDH assay (shown in data supplement Figure S2). Intracellular
Gb3 concentrations 2 days following siRNA transfection remained
unchanged compared to untreated cells (Figure 1C).
Gb3 impairs eNOS expression in HMiVECs
Gb3 (1024 mol/L) inhibited total eNOS expression in un-
stimulated as well as TNF-a (5 ng/ml, 5 hrs) stimulated
HMiVECs resulting in a 28% and 43% reduction, respectively
(n = 7; p = 0.002 and p= 0.001, respectively; Figure 2A). In
contrast, total eNOS expression in HMaVECs remained unaf-
fected (n = 6; p =NS; shown in data supplement Figure S3).
Furthermore, following Gb3 treatment of HMiVECs Ser1177
phosphorylation of eNOS was reduced under both basal
conditions (41% reduction, n = 7; p = 0.02; Figure 2B) and after
stimulation with TNF-a (5 ng/ml); 43% reduction, n = 7; p = 0.03;
Figure 2B). In contrast, Ser1177 pho eNOS expression in
HMaVECs remained unchanged following Gb3 treatment under
both baseline conditions and in TNF-a stimulated cells (n = 6;
p =NS; shown in data supplement Figure S4). In all cases,
expression of both total eNOS and Ser1177 phosphorylated eNOS
remained unchanged following GLA gene silencing (Figure 2C
and 2D).
Gb3 enhances iNOS expression in HMiVECs
TNF-a (5 ng/ml, 5 hrs) enhanced iNOS expression in HMi-
VECs by 1.5-fold (Figure 3A; p = 0.001). Treatment with Gb3
(1024 mol/L) for 48 hrs enhanced iNOS expression in unstimu-
lated HMiVECs by 1.7-fold, but not in TNF-a stimulated
HMiVECs (n= 7; p= 0.0014; Figure 3A). TNF-a enhanced
iNOS expression in HMaVECs by 1.6-fold (Figure 3B;
p = 0.009). In HMaVECs iNOS expression was unaffected by
Gb3 treatment independent of TNF-a stimulation (n= 7; p =NS;
Figure 3B). GLA gene silencing had no effect on expression of
iNOS (Figure 3C and 3D).
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Gb3 specifically enhances COX-2 but not COX-1
expression in HMiVECs
In unstimulated HMiVECs Gb3 (1024 mol/L) enhanced COX-
2 expression by 1.5-fold as compared to controls, but not in TNF-
a stimulated cells (n = 7; p,0.0001; Figure 4A). Interestingly, in
HMaVECs COX-2 expression was not affected by Gb3
irrespective of TNF-a stimulation (n= 7; p =NS, shown in data
supplement Figure S5).
TNF-a enhanced COX-1 expression in both HMiVECs and
HMaVECs by 1.5-fold and 1.4-fold, respectively (n = 4; p = 0.04
and p= 0.03, respectively; Figure 4B). COX-1 expression
remained unchanged in HMaVECs and HMiVECs following
Figure 1. Gb3 loading and alpha-Galactosidase A gene silencing. A. Incubation with Gb3 increased intracellular concentration of Gb3, as
measured by ELISA, by 2-folds in HMaVECs and HMiVECs (n = 4, p = 0.03 and p= 0.04, respectively, versus untreated control, B. Maximal a-Gal A
protein silencing of 70% occurred 48 hrs after transfection of HMaVECs with siRNA 3. Transfection of HMaVECs with Non-targeting (NT)-RNA did not
alter endothelial a-Gal A expression. Values are representative of at least 4 different experiments; all blots are normalized to GAPDH expression. C.
Intracellular Gb3 concentrations 2 days following siRNA transfection remained unchanged compared to untreated cells.
doi:10.1371/journal.pone.0036373.g001
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Gb3 treatment (n = 4; p =NS, Figure 4B). Again, GLA gene
silencing had no effect on expression (Figure 4C).
Gb3 enhances VCAM-1 but not ICAM-1 expression in
TNF-a stimulated HMiVECs
TNF-a (5 ng/ml, 5 hrs) enhanced VCAM-1 expression in both
HMiVECs and HMaVECs by 9.5-fold and 10.5-fold, respectively
(n = 6; p,0.001; Figure 5A and 5B). VCAM-1 expression in
HMiVECswas further enhanced byGb3 by 1.8-fold as compared to
TNF-a alone (n= 6; p = 0.0022; Figure 5A) while Gb3 did not
change TNF-a stimulated VCAM-1 expression in HMaVECs
(n= 6; p =NS;Figure 5B). ICAM-1 expression in bothHMaVECs
and HMiVECs remained unchanged following Gb3 treatment with
or without TNF-a stimulation (n= 4; p=NS, shown in data
supplement Figure S6). As shown in Figure 5C and 5D, GLA
gene silencing did not affect expression of VCAM-1.
Discussion
The experimental data gathered in this study contribute two
important novel messages to a better understanding of the
mechanisms involved in FD’s vasculopathy. First, the impairment
Figure 2. Gb3 impairs eNOS expression in HMiVECs. A. Gb3 inhibits total eNOS expression in TNF-a stimulated HMiVECs and under basal
conditions. Values are indicated as percent of unstimulated control. *p,0.05 vs unstimulated control; **p,0.05 vs TNF-a alone. B. Gb3 inhibits
Ser1177 pho eNOS expression in TNF-a stimulated HMiVECs and under basal conditions. Values are indicated as percent of unstimulated control.
*p,0.05 vs unstimulated control; **p,0.05 vs TNF-a alone. Values are representative of at least 4 different experiments; all blots are normalized to
GAPDH expression. C./D. In all cases expression remained unchanged following GLA gene silencing.
doi:10.1371/journal.pone.0036373.g002
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of endothelial function in FD patients is most likely caused by Gb3
as a consequence of intracellular accumulation, and not through a
pleiotropic phenomenon based on deficiency of GLA, as
demonstrated by our experiments comparing Gb3 loading to
GLA silencing. Hence, our results yield a mechanistic substitute
for hitherto existing evidence on FD-associated vasculopathy
mainly based on histopathology and imaging studies. Second, our
data demonstrate an enhanced sensitivity of HMiVECs to Gb3
accumulation, compared to HMaVECs, as shown by the
deregulation of key vasoactive pathways such as eNOS and
COX occurring primarily in HMiVECs. These findings support
previously observed clinical findings hinting an early and, often
initially silent involvement of the microcirculation in FD patients.
We selected a novel experimental setting so as to assess
comprehensively the effect of Gb3 accumulation with and without
a downregulation of GLA expression in human endothelial cells.
To this end, we purposely chose a time point after GLA silencing,
which was early enough so that it would not result in increased
Gb3 levels. Indeed, an eventual Gb3 accumulation following GLA
silencing would have rendered our experimental setup inappro-
Figure 3. Gb3 enhances iNOS expression in HMiVECs. A. Gb3 enhances iNOS expression in HMiVECs under basal conditions. TNF-a enhances
iNOS expression in HMiVECs. Values are indicated as percent of unstimulated control. *p,0.05 vs unstimulated control. B. TNF-a enhances iNOS
expression in HMaVECs. Values are indicated as percent of unstimulated control. *p,0.05 vs unstimulated control; Values are representative of at
least 4 different experiments; all blots are normalized to GAPDH expression. C./D. GLA gene silencing had no effect on expression of iNOS.
doi:10.1371/journal.pone.0036373.g003
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priate. The functional role of GLA in cultured cells has been
addressed in an earlier report where the authors showed twofold
increase in Gb3 expression when GLA was knocked down for 2
months and, most importantly, stated that in shorter times (such as
those in our experiments) it is reasonable not to see a spontaneous
accumulation of Gb3 following GLA silencing [9]. Thus, we were
able to establish a reproducible silencing of GLA using siRNA and
also exclude any toxic effect of the GLA silencing which would
have confounded our results substantially. The same holds true for
the evidence of Gb3 accumulation and toxicity in Gb3 treated
cells. It should be emphasized – although it has been repeatedly
indicated that the storage is exclusively in lysosomes and the
disease process rather mechanical [10] – that several studies
demonstrated Gb3 being not only present in lysosomes, but rather
widely distributed in other cellular structures including the
endoplasmatic reticulum, cell membrane, and nucleus [11].
Accordingly, there is increasing evidence suggesting that the wide
intracellular accumulation of Gb3 brings forth dysfunction of
other cellular key components involved in the regulation of
endothelial function [12,13]. Our observation was in fact, that
total eNOS and pho-eNOS, both associated with the cell
membrane, are downregulated in Gb3 loaded HMiVECs cells,
while iNOS expression was upregulated. The observed dysregu-
lation of the L-arginine/nitric oxide (NO) pathways in HMiVECs
cells may adversely affect vascular function and blood flow to vital
organs, thus contributing to the risk of an incipient vasculopathy
and provide a pathologic milieu for the accelerated development
of cardiovascular complications. Interestingly, such deregulations
of endothelial mediators were not present in GLA silenced cells,
regardless of whether HMiVECs or HMaVECs were used.
Indeed, expression of eNOS and iNOS was unchanged under
these conditions, thus underlining a key role of Gb3. While our
study may be the first detailed analysis comparing the effects of
GLA silencing versus Gb3 loading in endothelial cells, previous
studies focusing on eNOS and iNOS activity in the setting of a FD
associated vasculopathy support our current findings
[12,13,14,15,16].
Another group of enzymes, which are crucially involved in the
regulation of endothelial function are the cyclooxygenase isoforms
COX-1 and COX-2. We have demonstrated that COX-2
expression is enhanced in Gb3 treated HMiVECs, while COX-1
expression remains unaffected, suggesting that upregulation of
vasoconstrictive COX-2 derivates may contribute to microvascu-
lar dysfunction also in FD, as previously described for other
Figure 4. Gb3 enhances COX-2 expression in HMiVECs. A. Gb3 enhances COX-2 expression in HMiVECs under basal conditions. TNF-a
enhances COX-2 expression in HMiVECs. Values are indicated as percent of unstimulated control. *p,0.05 vs unstimulated control. B. TNF-a
enhanced COX-1 expression in both HMiVECs and HMaVECs by 1.5-fold and 1.4-fold, respectively. Values are representative of at least 4 different
experiments; all blots are normalized to GAPDH expression. C. GLA gene silencing had no effect on expression of COX-2.
doi:10.1371/journal.pone.0036373.g004
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experimental settings [17]. Generally, it has been demonstrated
that endothelium-dependent contractions particularly in arterial
hypertension and diabetes mellitus are COX-dependent and that
both COX-1 and COX-2 activity can mediate or enhance
endothelium-dependent contractions [18]. Of note, COX-2 can
act as a major source of the vasodilator PGI2, particularly under
conditions when NO bioavailability is diminishing [18]. Further-
more, it has been reported that receptor-induced endothelium-
dependent contractions were impaired in aortas of GLA knockout
mice, but could be restored by the nonspecific COX-inhibitor
indomethacin [19]. The current evidence on the aberrant vascular
reactivity in FD in this context can be attributed in part to changes
in endothelial COX-1 and COX-2 activity. However, COX-1 and
COX-2 appear to contribute to the vasculopathy in different ways,
e.g., specific inhibition of COX-1 improved endothelium-depen-
dent relaxation in aortas from GLA knockout mice, whereas
COX-2 inhibition exacerbated the endothelial dysfunction [19].
Indeed, COX-2-derived prostaglandins can play a compensatory
role for the decreased NO bioavailability [20,21], thus possibly
explaining some of the detrimental cardiovascular effects associ-
Figure 5. Gb3 enhances VCAM-1 expression in TNF-a stimulated HMiVECs. A. TNF-a enhances VCAM-1 expression in HMiVECs. Values are
indicated as percent of unstimulated control. *p,0.05 vs unstimulated control; Values are representative of at least 4 different experiments; all blots
are normalized to GAPDH expression. B. Gb3 enhances VCAM-1 expression in TNF-a stimulated HMaVECs and under basal conditions. Values are
indicated as percent of unstimulated control. *p,0.05 vs unstimulated control; **p,0.05 vs TNF-a alone. C./D. GLA gene silencing did not affect
expression of VCAM-1.
doi:10.1371/journal.pone.0036373.g005
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ated with COX-2 inhibitors [22]. Additionally, COXs are also
involved in the endothelial generation of reactive oxygen species, a
key factor in the generation of endothelium-dependent contrac-
tions [23,24]. Whether these effects can be translated into the
vasculopathy in FD is still a matter of debate and not entirely clear.
Silencing of GLA did not lead to any significant changes in COX-
1 or COX-2 expression in either HMiVECs or HMaVECs
underscoring once again a pivotal role of Gb3 levels in affecting
expression of key vasoactive enzymes.
The expression of adhesion molecules is an early step in vascular
disease both experimentally and in humans [25,26]. Indeed, the
plasma levels of the soluble form of such proteins are positively
related to outcome [26]. In this context, it is of interest that we
found that VCAM-1, but not ICAM expression is upregulated
following Gb3 treatment only in HMiVECs, suggesting that Gb3
induces a pro-inflammatory phenotype in FD. Increased plasma
levels of other endothelial atherosclerotic factors and leukocyte
adhesion-molecule expression have recently been demonstrated in
FD supporting our findings and directing towards a better
understanding of clinical manifestations [27,28,29]. Correspond-
ingly, cardio- and cerebrovascular complications like cerebral
white matter lesions are frequently found in FD, mainly attributed
to thrombo-embolic or ischemic events [30,31,32].
In summary, our findings add to the current evidence on the
mechanisms of vascular complications and their clinical sequelae in
patients with FD. Indeed, FD patients have a substantially limited
life expectancywhich takes its onset in early and extensive damage to
cardiovascular tissues. However, the pathophysiology of this specific
vasculopathy is far from being understood. Our findings demon-
strate that the phenotype of microvascular endothelial cells is
specifically altered by the intracellular accumulation of Gb3 leading
to a vasoconstrictive and pro-inflammatory phenotype. Of note, we
demonstrate that such changes do occur due to a direct effect ofGb3,
and not of GLA. The fact that the effects of Gb3 accumulation was
primarily seen in micro- and not in macrovascular endothelium is
consistent with previous observations that atherosclerosis as such is
not a consistent finding in FD [33]. Our data underscore an
enhanced susceptibility of HMiVECs to Gb3 accumulation
compared to HMaVECs. Although longer exposure to Gb3 may
result in similar effects also in HMaVECs, the fact that HMiVECs
manifest an earlier deregulation most probably resulting in
microvascular dysfunction is an important hint with respect to the
early pathophysiological changes, which may take place in FD
patients. It is thus conceivable that cardiac microvascular dysfunc-
tion maybe a landmark exam for early diagnosis and treatment of
FD patients. Other reports suggest that smooth muscle proliferation
in the arterial media layer may also contribute to the vasculopathy
seen in FD [34,35].
For the time being, treatment with enzyme replacement therapy
(ERT) is the best option for patients in developed countries.
Recombinant GLA is presumed to be removed from the systemic
circulation and subsequently transported to its site of action in
cellular lysosomes and, most importantly, not in the cytosol, as no
reversibility of tissue uptake or release into the circulation occurs
and the enzyme is only activated by the low pH before its
subsequent degradation in the lysosomes [36]. It has been shown
that ERT – given intravenously – results in a reduction of
endothelial Gb3 content [37]. However, not all patients, in
particular those with an advanced stage of the disease, benefit from
ERT. The latter might at least in part be explained by the fact that
ERT – although unfolding its full potential in the lysosomes – stops
further extralysosomal and thus pathogenic Gb3 accumulation in
line with still intact autoprotective cellular processes before some
kind of ‘‘point of no return’’ of cellular damage occurs.
We show indeed, that the enzyme deficiency as such is not a
major contributor to the pathophysiology, which is strongly
backed up by the fact that female carriers may suffer from vascular
complications as well. In fact, females and patients with an
advanced stage of the disease do not show changes in endothelial
Gb3 content as a surrogate marker to the clinical course under
ERT [38], raising the question whether ERT should be started as
early as possible in order to halt the pathophysiologic cascade of
the vasculopathy, even before specific clinical manifestations occur
and furthermore whether established and thus supplemental
treatment options such as anti-platelet therapy and/or lipid
lowering/antihypertensive drugs should be indicated for patients
with FD should be conceived. We conclude herewith that
vasculopathy in FD is directly caused by intracellular Gb3
accumulation primarily in microvascular endothelial cells, while
deficiency of GLA alone does not cause any deregulation of key
vasoactive mediators. HMiVECs, as opposed to HMaVECs, seem
to be affected earlier and more severely by Gb3 accumulation and
this notion may prove fundamental for future progresses in early
diagnosis and treatment of FD patients.
Supporting Information
Figure S1 Morphological examination under a light microscope
did not reveal any morphological changes (Figure S1).
(TIF)
Figure S2 A maximal GLA protein silencing was observed
48 hrs after transfection in the absence of any toxic effect as
measured by LDH assay.
(TIF)
Figure S3 Total eNOS expression in HMaVECs remained
unaffected by Gb3 loading.
(TIF)
Figure S4 Ser1177 pho eNOS expression in HMaVECs
remained unchanged following Gb3 treatment under both
baseline conditions and in TNF-a stimulated cells.
(TIF)
Figure S5 In HMaVECs COX-2 expression was not affected by
Gb3 irrespective of TNF-a stimulation.
(TIF)
Figure S6 ICAM-1 expression in both HMaVECs and HMi-
VECs remained unchanged following Gb3 treatment with or
without TNF-a stimulation.
(TIF)
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